Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1989 Jul;48(7):586–589. doi: 10.1136/ard.48.7.586

Platelet serotonin in systemic sclerosis.

P S Klimiuk 1, A Grennan 1, C Weinkove 1, M I Jayson 1
PMCID: PMC1003821  PMID: 2774700

Abstract

Platelet serotonin concentrations were measured in 43 patients with systemic sclerosis, in 11 patients with primary Raynaud's phenomenon, and in 38 normal controls. Patients with the CREST variant (calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly, telangiectasia) had significantly lower platelet serotonin concentrations than normal controls. Patients with diffuse systemic sclerosis had normal platelet serotonin concentrations. In patients with CREST treatment with ketanserin, a specific serotonin antagonist, normalised platelet serotonin concentrations. These data provide further evidence suggesting that in systemic sclerosis, particularly the CREST variant, there is widespread platelet activation.

Full text

PDF
586

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Campbell P. M., LeRoy E. C. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum. 1975 May;4(4):351–368. doi: 10.1016/0049-0172(75)90017-7. [DOI] [PubMed] [Google Scholar]
  2. Castor C. W., Ritchie J. C., Williams C. H., Jr, Scott M. E., Whitney S. L., Myers S. L., Sloan T. B., Anderson B. E. Connective tissue activation. XIV. Composition and actions of a human platelet autacoid mediator. Arthritis Rheum. 1979 Mar;22(3):260–272. doi: 10.1002/art.1780220308. [DOI] [PubMed] [Google Scholar]
  3. Gillis C. N., Pitt B. R. The fate of circulating amines within the pulmonary circulation. Annu Rev Physiol. 1982;44:269–281. doi: 10.1146/annurev.ph.44.030182.001413. [DOI] [PubMed] [Google Scholar]
  4. HALPERN A., KUHN P. H., SHAFTEL H. E., SAMUELS S. S., SHAFTEL N., SELMAN D., BRICH H. G. Raynaud's disease, Raynaud's phenomenon, and serotonin. Angiology. 1960 Jun;11:151–167. doi: 10.1177/000331976001100301. [DOI] [PubMed] [Google Scholar]
  5. Hugh D., Grennan A., Abugila M. A., Weinkove C. Ascorbic acid as an antioxidant in measurements of catecholamines in plasma. Clin Chem. 1987 Apr;33(4):569–571. [PubMed] [Google Scholar]
  6. Jauernig R. A., Moulds R. F. A human arterial preparation for studying the effects of vasoactive agents. Circ Res. 1978 Mar;42(3):363–368. doi: 10.1161/01.res.42.3.363. [DOI] [PubMed] [Google Scholar]
  7. Jayson M. I. Systemic sclerosis--a microvascular disorder? J R Soc Med. 1983 Aug;76(8):635–642. doi: 10.1177/014107688307600804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kahaleh M. B., Osborn I., Leroy E. C. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med. 1982 May;96(5):610–613. doi: 10.7326/0003-4819-96-5-610. [DOI] [PubMed] [Google Scholar]
  9. Kallenberg C. G., Vellenga E., Wouda A. A., The T. H. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. J Rheumatol. 1982 Nov-Dec;9(6):878–884. [PubMed] [Google Scholar]
  10. Moulds R. F., Iwanov V., Medcalf R. L. The effects of platelet-derived contractile agents on human digital arteries. Clin Sci (Lond) 1984 Apr;66(4):443–451. doi: 10.1042/cs0660443. [DOI] [PubMed] [Google Scholar]
  11. RODDIE I. C., SHEPHERD J. T., WHELAN R. F. The action of 5-hydroxytryptamine on the blood vessels of the human hand and forearm. Br J Pharmacol Chemother. 1955 Dec;10(4):445–450. doi: 10.1111/j.1476-5381.1955.tb00102.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Riddle J. M., Bluhm G. B., Pitchford W. C., McElroy H., Jimenea C., Leisen J., Venkatasubramanian K. A comparative study of platelet reactivity in arthritis. Ann N Y Acad Sci. 1981;370:22–29. doi: 10.1111/j.1749-6632.1981.tb29717.x. [DOI] [PubMed] [Google Scholar]
  13. Rodnan G. P., Myerowitz R. L., Justh G. O. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 1980 Nov;59(6):393–408. doi: 10.1097/00005792-198011000-00001. [DOI] [PubMed] [Google Scholar]
  14. Seibold J. R., Jageneau A. H. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor. Arthritis Rheum. 1984 Feb;27(2):139–146. doi: 10.1002/art.1780270204. [DOI] [PubMed] [Google Scholar]
  15. Small R., Macarak E., Fisher A. B. Production of 5-hydroxyindoleacetic acid from serotonin by cultured endothelial cells. J Cell Physiol. 1977 Feb;90(2):225–231. doi: 10.1002/jcp.1040900208. [DOI] [PubMed] [Google Scholar]
  16. Stranden E., Roald O. K., Krohg K. Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin. Br Med J (Clin Res Ed) 1982 Oct 16;285(6348):1069–1071. doi: 10.1136/bmj.285.6348.1069. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES